FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130364364> ?p ?o ?g. }

• W3130364364 endingPage "431" @default.
• W3130364364 startingPage "425" @default.
• W3130364364 abstract "Adjuvant treatment for post-menopausal women with early breast cancer (BC) includes aromatase inhibitors (AI), known to decrease bone mineral density (BMD). In this study, we investigate whether denosumab is a valid second option for patients unable to receive standard adjuvant i.v. zoledronic acid (ZA). In total, 212 patients have been evaluated after they did not receive ZA. Of those 194 were included. After evaluation by an endocrinologist, all patients were offered ZA as their first choice and 15% accepted (N = 29). The remaining 85% were offered denosumab (N = 165). All patients were followed prospectively with blood tests up to 24 months. DXA scans were performed at baseline and 24 months. No difference was observed between the two treatment groups at baseline, with regard to anthropometry and standard biochemistry. Markers of bone turnover (p-PINP, p-CTX, p-bone-specific alkaline phosphatase and p-osteocalcin) all showed significant suppression compared to baseline and remained suppressed throughout the 2 years. BMD showed small and significant increases at the spine (0.024 g/cm2) and total hip (0.019 g/cm2) in the denosumab group but no change at the femoral neck(-0.011g/cm2). In the ZA group, we observed no significant change at the spine (0.015 g/cm2) and total hip (-0.001g/cm2) and a small significant decrease at the femoral neck (-0.037 g/cm2). However, when we compared BMD change between the treatment groups, we found no significant difference.Conclusions: Our data indicate that for BC patients in AI treatment who refused or were not able to receive ZA treatment, denosumab might be recommended as a second choice. Regarding markers of bone turnover and BMD denosumab is equal to ZA.Summary: Women with early breast cancer receiving anti-estrogen treatment are at risk of developing osteoporosis.We followed 194 women receiving zoledronic acid (ZA) or denosumab for up to 2 years.We find that with regard to bone protection, denosumab is a viable alternative to ZA and might be recommended as a second choice." @default.
• W3130364364 created "2021-03-01" @default.
• W3130364364 creator A5021171228 @default.
• W3130364364 creator A5049916704 @default.
• W3130364364 creator A5054680126 @default.
• W3130364364 creator A5057314845 @default.
• W3130364364 creator A5069431123 @default.
• W3130364364 date "2021-06-13" @default.
• W3130364364 modified "2023-09-27" @default.
• W3130364364 title "Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study" @default.
• W3130364364 cites W1757407923 @default.
• W3130364364 cites W1834183965 @default.
• W3130364364 cites W1977297257 @default.
• W3130364364 cites W1980617781 @default.
• W3130364364 cites W2006638597 @default.
• W3130364364 cites W2015015687 @default.
• W3130364364 cites W2031117993 @default.
• W3130364364 cites W2095989308 @default.
• W3130364364 cites W2117902460 @default.
• W3130364364 cites W2122786185 @default.
• W3130364364 cites W2144133819 @default.
• W3130364364 cites W2163949875 @default.
• W3130364364 cites W2214665719 @default.
• W3130364364 cites W2738899576 @default.
• W3130364364 cites W2792392055 @default.
• W3130364364 cites W2910054564 @default.
• W3130364364 cites W2912993657 @default.
• W3130364364 cites W4252714226 @default.
• W3130364364 doi "https://doi.org/10.1080/00365513.2021.1929447" @default.
• W3130364364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34120544" @default.
• W3130364364 hasPublicationYear "2021" @default.
• W3130364364 type Work @default.
• W3130364364 sameAs 3130364364 @default.
• W3130364364 citedByCount "2" @default.
• W3130364364 countsByYear W31303643642022 @default.
• W3130364364 crossrefType "journal-article" @default.
• W3130364364 hasAuthorship W3130364364A5021171228 @default.
• W3130364364 hasAuthorship W3130364364A5049916704 @default.
• W3130364364 hasAuthorship W3130364364A5054680126 @default.
• W3130364364 hasAuthorship W3130364364A5057314845 @default.
• W3130364364 hasAuthorship W3130364364A5069431123 @default.
• W3130364364 hasConcept C121608353 @default.
• W3130364364 hasConcept C126322002 @default.
• W3130364364 hasConcept C126894567 @default.
• W3130364364 hasConcept C170033053 @default.
• W3130364364 hasConcept C2775854910 @default.
• W3130364364 hasConcept C2776166826 @default.
• W3130364364 hasConcept C2776286101 @default.
• W3130364364 hasConcept C2776326535 @default.
• W3130364364 hasConcept C2776541429 @default.
• W3130364364 hasConcept C2776886416 @default.
• W3130364364 hasConcept C2778504769 @default.
• W3130364364 hasConcept C29456083 @default.
• W3130364364 hasConcept C530470458 @default.
• W3130364364 hasConcept C71924100 @default.
• W3130364364 hasConceptScore W3130364364C121608353 @default.
• W3130364364 hasConceptScore W3130364364C126322002 @default.
• W3130364364 hasConceptScore W3130364364C126894567 @default.
• W3130364364 hasConceptScore W3130364364C170033053 @default.
• W3130364364 hasConceptScore W3130364364C2775854910 @default.
• W3130364364 hasConceptScore W3130364364C2776166826 @default.
• W3130364364 hasConceptScore W3130364364C2776286101 @default.
• W3130364364 hasConceptScore W3130364364C2776326535 @default.
• W3130364364 hasConceptScore W3130364364C2776541429 @default.
• W3130364364 hasConceptScore W3130364364C2776886416 @default.
• W3130364364 hasConceptScore W3130364364C2778504769 @default.
• W3130364364 hasConceptScore W3130364364C29456083 @default.
• W3130364364 hasConceptScore W3130364364C530470458 @default.
• W3130364364 hasConceptScore W3130364364C71924100 @default.
• W3130364364 hasIssue "6" @default.
• W3130364364 hasLocation W31303643641 @default.
• W3130364364 hasLocation W31303643642 @default.
• W3130364364 hasOpenAccess W3130364364 @default.
• W3130364364 hasPrimaryLocation W31303643641 @default.
• W3130364364 hasRelatedWork W1972885432 @default.
• W3130364364 hasRelatedWork W2064949063 @default.
• W3130364364 hasRelatedWork W2116817852 @default.
• W3130364364 hasRelatedWork W2792664125 @default.
• W3130364364 hasRelatedWork W2982378025 @default.
• W3130364364 hasRelatedWork W3028678549 @default.
• W3130364364 hasRelatedWork W3029520013 @default.
• W3130364364 hasRelatedWork W3083546569 @default.
• W3130364364 hasRelatedWork W3121139991 @default.
• W3130364364 hasRelatedWork W4286686858 @default.
• W3130364364 hasVolume "81" @default.
• W3130364364 isParatext "false" @default.
• W3130364364 isRetracted "false" @default.
• W3130364364 magId "3130364364" @default.
• W3130364364 workType "article" @default.